I don’t think we can confidently say that “during our research, we have come to realize…” You can say that based on preclinical mice models, and the drug’s MOA, we anticipate that CT-189 blah blah. All of the Phase I/II/III stuff are mock trial designs with NO real data. We don’t know what will actually happen. a. Differentiation
The assignment is to design a development plan and prepare a summary presentation for outlicensing. This will involve deciding which therapeutic indication is most appropriate for this compound, evaluating its competitive viability, estimate its commercial potential, prepare a target product profile, provide a marketing perspective of the intended consumer, design a clinical development plan with […]